Wu Haiyang, Sun Zaijie, Zeng Guiping, Yang Jia, Deng Changxu, Li Cheng
Department of Orthopaedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Department of Orthopaedic Surgery, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China.
Ann Surg Oncol. 2025 May;32(5):3724-3740. doi: 10.1245/s10434-025-16978-7. Epub 2025 Feb 19.
Ewing sarcoma (ES) is a rare type of cancer that primarily affects children and young adults. In recent years, there have been notable advancements in the treatment of ES due to the introduction of neoadjuvant chemotherapy and targeted therapy, as well as a wealth of related studies in this field published by scholars around the world. However, there is still a lack of a comprehensive report to aid researchers in quickly understanding the knowledge structure and emerging trends of this area.
We conducted a comprehensive search in the Web of Science Core Collection for relevant studies published from 2000 to 2023. To conduct a thorough scientometric analysis and create network visualizations, we utilized three different tools, namely, an online analysis platform, CiteSpace, and VOSviewer. These tools enabled us to examine various aspects such as annual publication output; active journals; contributions from countries, institutions, and authors; references; and keywords.
A total of 5163 qualified publications were included. The annual number of publications on ES showed a significant linear growth trend (R = 0.927). The USA stands out as the most productive country. The institution and author that contributed the largest number of papers were University of Texas System and Dirksen U., respectively. As can be seen from highly cited studies and reference analysis and application of Surveillance, Epidemiology, and End Results (SEER) database, preclinical and clinical trials of multiple combination treatment strategies, especially with different approach of immunotherapy such as CAR-T cells or anti-PD-1 antibody for ES, are the primary focus of the current study. Keyword analysis identified several research topics including immunotherapy, tumor microenvironment, microRNA, biomarkers, EWSR1, metastasis, epigenetics, epithelial mesenchymal transition, mesenchymal stem cell, and combination therapy, which have emerged as frontiers in the field and hold significant potential as ongoing research hotspots.
ES is a field that has continued to receive increasing attention in recent years. Harnessing current immunotherapy approaches to improve outcomes of patients with ES is an area of intense interest. This study has provided a comprehensive knowledge map, development landscape, and future directions for ES research, and offered a practical and valuable reference for scholars to obtain better understanding of the current state of research in this field.
尤因肉瘤（ES）是一种罕见的癌症，主要影响儿童和年轻人。近年来，由于新辅助化疗和靶向治疗的引入，以及世界各地学者在该领域发表的大量相关研究，ES的治疗取得了显著进展。然而，仍然缺乏一份全面的报告来帮助研究人员快速了解该领域的知识结构和新出现的趋势。
我们在科学网核心合集（Web of Science Core Collection）中对2000年至2023年发表的相关研究进行了全面检索。为了进行全面的科学计量分析并创建网络可视化，我们使用了三种不同的工具，即在线分析平台、CiteSpace和VOSviewer。这些工具使我们能够考察各个方面，如年度出版物产出、活跃期刊、国家、机构和作者的贡献、参考文献以及关键词。
共纳入5163篇合格出版物。ES的年度出版物数量呈现出显著的线性增长趋势（R = 0.927）。美国是产出最多的国家。贡献论文数量最多的机构和作者分别是德克萨斯大学系统和Dirksen U.。从高被引研究以及监测、流行病学和最终结果（SEER）数据库的参考文献分析和应用可以看出，多种联合治疗策略的临床前和临床试验，特别是针对ES的不同免疫治疗方法，如嵌合抗原受体T细胞（CAR-T）或抗程序性死亡蛋白1（PD-1）抗体，是当前研究的主要重点。关键词分析确定了几个研究主题，包括免疫治疗、肿瘤微环境、微小RNA、生物标志物、尤文肉瘤断裂区1（EWSR1）、转移、表观遗传学、上皮-间质转化、间充质干细胞和联合治疗，这些已成为该领域的前沿，并作为正在进行的研究热点具有巨大潜力。
ES是近年来持续受到越来越多关注的领域。利用当前的免疫治疗方法改善ES患者的治疗效果是一个备受关注的领域。本研究为ES研究提供了全面的知识图谱、发展格局和未来方向，并为学者更好地了解该领域的研究现状提供了实用且有价值的参考。
